🇪🇺 Reclaiming Europe’s Life Sciences Edge: Strategic IP & Regulatory Insights into the Proposed EU Biotech Act
Post

🇪🇺 Reclaiming Europe’s Life Sciences Edge: Strategic IP & Regulatory Insights into the Proposed EU Biotech Act

On December 16, 2025, the European Commission officially published its long-awaited proposal for the European Biotech Act. Designed as “Pillar 1” of a broader life sciences competitiveness strategy, this legislation introduces unprecedented regulatory and IP incentives aimed at keeping high-tech biomanufacturing and clinical research within the European Union. Facing intense global competition from the U.S....

🇨🇳 China’s 2026 Foreign Trade Law: Strategic Integration of IP, Trade Sanctions, and Licensing Compliance
Post

🇨🇳 China’s 2026 Foreign Trade Law: Strategic Integration of IP, Trade Sanctions, and Licensing Compliance

On March 1, 2026, China officially brought into force its revised Foreign Trade Law, marking the most significant structural overhaul of the country’s international trade governance in over two decades. Approved by the Standing Committee of the National People’s Congress, this updated statute explicitly integrates Intellectual Property (IP) rights into foreign trade enforcement for the...

🇨🇳 Modernizing China’s Life Sciences IP Infrastructure: Strategic Impact of the Revised Drug Administration Regulations
Post

🇨🇳 Modernizing China’s Life Sciences IP Infrastructure: Strategic Impact of the Revised Drug Administration Regulations

On May 15, 2026, the revised Implementing Regulations of the Drug Administration Law officially came into effect across the People’s Republic of China, following their formal promulgation by the State Council on January 27, 2026. Designed to incentivize clinical innovation while establishing strict, full-lifecycle accountability, these regulatory updates codify statutory market exclusivity, regulatory data protection...